Biological Products, (No Diagnostic Substances)
Standard Industrial Classification: SIC 2836
Industry Insider Sentiment Analysis
The Biological Products, (No Diagnostic Substances) sector (SIC 2836) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-07 00:05 | 2026-03-04 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% owner | BUY | $5.80 | 66,818 | $387,625 | 90,000 |
| 2026-03-07 04:00 | 2026-03-04 | APGE | Apogee Therapeutics Inc. | Dambkowski Carl | Officer | OPT+S | $71.06 | 5,500 | $390,825 | 209,773 |
| 2026-03-07 02:22 | 2026-03-04 | KRYS | Krystal Biotech, Inc. | Krishnan Krish S | Director, Officer, 10% owner | SELL | $263.17 | 25,000 | $6,579,165 | 1,475,253 |
| 2026-03-07 02:23 | 2026-03-04 | KRYS | Krystal Biotech, Inc. | Krishnan Suma | Director, Officer, 10% owner | SELL | $263.21 | 25,000 | $6,580,270 | 1,403,155 |
| 2026-03-06 00:03 | 2026-03-04 | TARS | Tarsus Pharmaceuticals, Inc. | Neervannan Seshadri | Officer | SELL | $76.67 | 8,366 | $641,421 | 70,817 |
| 2026-03-06 01:45 | 2026-03-03 | TECX | Tectonic Therapeutic, Inc. | McNamara Peter | Officer | SELL | $23.53 | 3,299 | $77,627 | 58,832 |
| 2026-03-06 00:30 | 2026-02-11 | TECX | Tectonic Therapeutic, Inc. | REICIN ALISE | Director, Officer | BUY | $21.10 | 2,500 | $52,750 | 127,030 |
| 2026-03-06 04:05 | 2026-03-03 | ADPT | Adaptive Biotechnologies Corporation | GRIFFIN MICHELLE RENEE | Director | OPT+S | $15.30 | 48,044 | $735,073 | 15,394 |
| 2026-03-06 03:42 | 2026-03-03 | ADPT | Adaptive Biotechnologies Corporation | RUBINSTEIN JULIE | Officer | OPT+S | $16.09 | 92,823 | $1,493,429 | 575,235 |
| 2026-03-06 03:02 | 2026-03-04 | LONA | LeonaBio, Inc. | CHURCH KEVIN | Officer | OPT+S | $5.37 | 1,359 | $7,298 | 25,178 |
| 2026-03-06 03:06 | 2026-03-04 | LONA | LeonaBio, Inc. | Worthington Mark | Officer | OPT+S | $5.37 | 1,328 | $7,131 | 18,376 |
| 2026-03-06 03:10 | 2026-03-04 | LONA | LeonaBio, Inc. | Renninger Robert | Officer | OPT+S | $5.37 | 906 | $4,865 | 15,851 |
| 2026-03-06 03:14 | 2026-03-04 | LONA | LeonaBio, Inc. | Litton Mark James | Director, Officer | OPT+S | $5.37 | 5,156 | $27,688 | 57,926 |
| 2026-03-06 02:59 | 2026-03-04 | LONA | LeonaBio, Inc. | San Martin Javier | Officer | OPT+S | $5.37 | 1,720 | $9,236 | 15,887 |
| 2026-03-06 01:24 | 2026-03-04 | GLUE | Monte Rosa Therapeutics, Inc. | Dunn Edmund | Officer | SELL | $17.96 | 139 | $2,496 | 22,554 |
| 2026-03-05 00:45 | 2026-02-27 | INKT | MiNK Therapeutics, Inc. | Ryan Barbara | Director | SELL | $10.85 | 500 | $5,426 | 21,906 |
| 2026-03-05 00:50 | 2026-03-02 | GLUE | Monte Rosa Therapeutics, Inc. | Warmuth Markus | Director, Officer | SELL | $17.92 | 5,466 | $97,974 | 613,471 |
| 2026-03-05 02:00 | 2026-03-02 | KYMR | Kymera Therapeutics, Inc. | Gollob Jared | Officer | SELL | $87.24 | 10,508 | $916,669 | 117,134 |
| 2026-03-05 02:00 | 2026-03-02 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | Officer | SELL | $87.50 | 12,471 | $1,091,231 | 232,588 |
| 2026-03-05 00:05 | 2026-03-02 | VCEL | Vericel Corp | Flynn Sean C. | Officer | OPT+S | $35.18 | 21,421 | $753,531 | 1,262 |
| 2026-03-05 00:05 | 2026-03-02 | VCEL | Vericel Corp | Halpin Michael | Officer | SELL | $35.30 | 10,305 | $363,767 | 16,080 |
| 2026-03-05 00:49 | 2026-03-03 | EDIT | Editas Medicine, Inc. | Parison Amy | Officer | SELL | $2.02 | 474 | $957 | 15,434 |
| 2026-03-05 00:48 | 2026-03-03 | EDIT | Editas Medicine, Inc. | Burkly Linda | Officer | SELL | $2.02 | 749 | $1,513 | 68,028 |
| 2026-03-05 00:05 | 2026-03-02 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% owner | BUY | $5.76 | 71,411 | $411,620 | 85,000 |
| 2026-03-05 00:30 | 2026-03-02 | KYMR | Kymera Therapeutics, Inc. | Booth Bruce | Director | SELL | $90.13 | 81,866 | $7,378,583 | 675,341 |
| 2026-03-05 02:00 | 2026-03-02 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | Officer | SELL | $86.54 | 5,958 | $515,594 | 73,810 |
| 2026-03-05 04:00 | 2026-03-02 | APGE | Apogee Therapeutics Inc. | Henderson Jane | Officer | SELL | $70.22 | 2,000 | $140,431 | 181,371 |
| 2026-03-05 03:58 | 2026-03-02 | ADPT | Adaptive Biotechnologies Corporation | ROBINS HARLAN S | Officer | SELL | $16.19 | 24,233 | $392,330 | 1,155,291 |
| 2026-03-05 02:56 | 2026-03-02 | HALO | HALOZYME THERAPEUTICS, INC. | Torley Helen | Director, Officer | OPT+S | $69.52 | 50,000 | $3,476,155 | 767,780 |
| 2026-03-05 01:42 | 2026-03-02 | ALLO | Allogene Therapeutics Inc. | Beneski Benjamin Machinas | Officer | SELL | $2.60 | 7,132 | $18,543 | 203,040 |
| 2026-03-05 00:56 | 2026-03-03 | EDIT | Editas Medicine, Inc. | O'Neill Gilmore Neil | Director, Officer | SELL | $2.02 | 5,394 | $10,894 | 263,693 |
| 2026-03-05 00:38 | 2026-03-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Borgeson Blake | Director | SELL | $3.46 | 170,000 | $588,200 | 6,259,863 |
| 2026-03-05 00:28 | 2026-03-02 | ATRA | Atara Biotherapeutics, Inc. | Nguyen AnhCo | Director, Officer | SELL | $5.09 | 2,996 | $15,237 | 61,978 |
| 2026-03-05 00:28 | 2026-03-02 | ATRA | Atara Biotherapeutics, Inc. | Grant-Huerta Yanina | Officer | SELL | $5.08 | 2,104 | $10,691 | 31,750 |
| 2026-03-04 00:20 | 2026-03-02 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | Officer | OPT+S | $45.20 | 5,000 | $226,011 | 12,965 |
| 2026-03-04 00:25 | 2026-02-27 | MAZE | Maze Therapeutics, Inc. | Dandekar Atul | Officer | OPT+S | $45.43 | 7,500 | $340,724 | 10,503 |
| 2026-03-04 00:05 | 2026-03-02 | ALEC | Alector Inc. | Berkley Neil Lindsay | Officer | SELL | $2.12 | 29,649 | $62,954 | 344,660 |
| 2026-03-04 02:01 | 2026-03-03 | ALEC | Alector Inc. | Wong-Sarad Grace | Officer | SELL | $2.08 | 3,367 | $7,012 | 107,465 |
| 2026-03-04 00:05 | 2026-03-02 | ALEC | Alector Inc. | Wong-Sarad Grace | Officer | SELL | $2.12 | 8,071 | $17,138 | 110,832 |
| 2026-03-04 00:05 | 2026-03-02 | ALEC | Alector Inc. | Rosenthal Arnon | Director, Officer | SELL | $2.12 | 81,864 | $173,822 | 2,338,176 |
| 2026-03-04 00:05 | 2026-03-02 | FENC | FENNEC PHARMACEUTICALS INC. | Raykov Rosty | Director | OPT+S | $8.36 | 10,079 | $84,260 | 103,996 |
| 2026-03-04 00:06 | 2026-02-27 | ZIVO | Zivo Bioscience, Inc. | YALDOO LAITH L | Director, 10% owner | BUY | $9.72 | 1,543 | $14,998 | 583,615 |
| 2026-03-04 05:42 | 2026-02-27 | ABOS | Acumen Pharmaceuticals, Inc. | Meisner Derek M | Officer | OPT+S | $3.01 | 9,406 | $28,311 | 173,999 |
| 2026-03-04 05:09 | 2026-03-02 | RVMD | Revolution Medicines, Inc. | GOLDSMITH MARK A | Director, Officer | OPT+S | $101.23 | 36,000 | $3,644,352 | 64,424 |
| 2026-03-04 03:51 | 2026-02-27 | ADPT | Adaptive Biotechnologies Corporation | ROBINS CHAD M | Director, Officer | SELL | $15.85 | 524,998 | $8,320,588 | 1,934,247 |
| 2026-03-04 02:33 | 2026-03-02 | KRYS | Krystal Biotech, Inc. | ROMANO KATHRYN | Officer | OPT+S | $267.60 | 750 | $200,700 | 22,366 |
| 2026-03-04 02:28 | 2026-02-27 | KRYS | Krystal Biotech, Inc. | JANNEY DANIEL | Director | SELL | $275.59 | 11,803 | $3,252,824 | 73,293 |
| 2026-03-04 00:10 | 2026-03-02 | MRNA | Moderna, Inc. | Klinger Shannon Thyme | Officer | OPT+S | $52.29 | 13,885 | $726,047 | 59,689 |
| 2026-03-03 20:10 | 2026-03-02 | VIR | Vir Biotechnology, Inc. | SATO VICKI L | Director | SELL | $9.51 | 22,000 | $209,180 | 1,122,391 |
| 2026-03-03 01:02 | 2026-02-27 | GLUE | Monte Rosa Therapeutics, Inc. | Dunn Edmund | Officer | OPT+S | $18.09 | 25,700 | $464,887 | 22,693 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Biological Products, (No Diagnostic Substances) sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2836) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Biological Products, (No Diagnostic Substances)
Every transaction in the Biological Products, (No Diagnostic Substances) industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.